27 Sep 2024

Xbrane provides update from Scientific Advice with US FDA on Xdivane™ (Opdivo® biosimilar candidate)

28 Aug 2024

Xbrane Biopharma releases Interim Report for January-June 2024

23 Aug 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2024 on August 28, 2024

12 Aug 2024

Xbrane provides update on the ongoing out-licensing of Xdivane™ (nivolumab biosimilar candidate) and XB003 (Cimzia® biosimilar candidate) and its financial position

01 Aug 2024

Xbrane to regain full rights to BIIB801, a proposed biosimilar referencing CIMZIA®

16 Jul 2024

Xbrane provides update on its development portfolio

08 Jul 2024

Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate

22 May 2024

Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® – and run an active partnering process

16 May 2024

Xbrane Biopharma releases Interim Report for January-March 2024

13 May 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024

10 May 2024

Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US

02 May 2024

Announcement from Xbrane Biopharma’s annual general meeting

21 Apr 2024

Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate

02 Apr 2024

Notice of annual general meeting in Xbrane Biopharma AB

01 Apr 2024

Change of number of shares and votes in Xbrane